Sugi Predict

Sugi Predict / Compounds / SCHEMBL4016155

SCHEMBL4016155

SCHEMBL4016155

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 3/20 0.58
▸ BRAF P15056 3/20 0.58
▸ MAPT P10636 2/20 0.57
▸ KIT P10721 7/20 0.55
▸ MAPK14 Q16539 7/20 0.55
▸ KDR P35968 6/20 0.55
▸ LCK P06239 3/20 0.55
▸ SRC P12931 2/20 0.55
▸ HTT P42858 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ CSF1R P07333 2/20 0.54
▸ KCNK3 O14649 2/20 0.54
▸ KCNK9 Q9NPC2 1/20 0.54
▸ POLB P06746 2/20 0.52
▸ APEX1 P27695 1/20 0.52
▸ KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29536884 0.92 BRAF (0.58) RAF1BRAFMAPTKITMAPK14
SCHEMBL2887561 0.92 BRAF (0.58) RAF1BRAFMAPTKITMAPK14
SCHEMBL22915771 0.87 MEN1 (0.54) MAPTKDRLCKHTTMEN1
SCHEMBL21911828 0.84 NPC1 (0.50) MAPTMEN1RAB9AKMT2AKCNK3
SCHEMBL25423049 0.83 RXFP1 (0.53) RAF1BRAFMAPTKITMAPK14
SCHEMBL5495420 0.82 LIPE (0.49) RAF1BRAFMAPTKDRSRC
SCHEMBL5491254 0.82 KCNQ3 (0.47) BRAFMAPTKITHTTMEN1
SCHEMBL1517349 0.82 MAPK14 (0.51) RAF1BRAFMAPTKITMAPK14
SCHEMBL5500166 0.82 RXFP1 (0.56) MAPT
SCHEMBL3523028 0.82 RXFP1 (0.58) HTTRAB9AKMT2AKCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108467369-B Biaryl amide compounds as kinase inhibitors 诺华股份有限公司 2021-08-20 — — CN disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 — — EP disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
EP-3299367-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2018-03-28 — — EP disclosed
EP-2970216-B1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2017-11-01 — — EP disclosed
US-20080096883-A1 Trifluoromethyl substituted benzamides as kinase inhibitors NOVARTIS AG (CH) 2008-04-24 — — US disclosed
US-20080096883-A1 Trifluoromethyl substituted benzamides as kinase inhibitors NOVARTIS AG (CH) 2008-04-24 — — US disclosed
WO-2008008821-A2 USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS NOVARTIS AG (CH) 2008-01-17 — — WO disclosed
WO-2008008821-A2 USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS NOVARTIS AG (CH) 2008-01-17 — — WO disclosed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 — — EP disclosed
EP-1778640-A1 TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS Novartis AG (CH) 2007-05-02 — — EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 — — WO disclosed
WO-2006015859-A1 TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-02-16 — — WO disclosed
US-20060035897-A1 Trifluoromethyl substituted benzamides as kinase inhibitors NOVARTIS AG (CH) 2006-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096883-A1 Trifluoromethyl substituted benzamides as kinase inhibitors MAP3K1, MAP3K20, MAP3K2 RAF1 28/4885BRAF 6/4885MAPT 2516/4885
US-20060035897-A1 Trifluoromethyl substituted benzamides as kinase inhibitors ABL1, ERBB2, EPHB2 RAF1 32/4885BRAF 6/4885MAPT 3074/4885
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS RAF1 2/4885BRAF 1/4885MAPT 1965/4885
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 RAF1 118/4885BRAF 100/4885MAPT 4333/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS RAF1 2/4885BRAF 1/4885MAPT 1965/4885
US-10245267-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS RAF1 2/4885BRAF 1/4885MAPT 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.